Figure 2
Classification of RS into risk-of-death categories and Kaplan-Meier estimates of RS survival according to those categories. The high-risk group includes patients presenting with a poor ECOG PS > 1, irrespective of TP53 status and type of response to RS induction treatment (Events/N, 28/30; median survival, 7.8 months; 95% CI, 2.5-13.1 months). The intermediate-risk group includes patients presenting with a good ECOG PS ≤ 1 but harboring TP53 disruption or not achieving CR after RS induction treatment despite being wild type on TP53 (Events/N, 23/41; median survival, 24.6 months; 95% CI, 15.8-33.4 months). The low-risk group includes patients who presented with a good ECOG PS ≤ 1, had no TP53 disruption, and achieved CR after RS induction treatment (Events/N, 2/11; median survival, not reached; 5-year survival, 70%; 95% CI, 34.4%-100%).

Classification of RS into risk-of-death categories and Kaplan-Meier estimates of RS survival according to those categories. The high-risk group includes patients presenting with a poor ECOG PS > 1, irrespective of TP53 status and type of response to RS induction treatment (Events/N, 28/30; median survival, 7.8 months; 95% CI, 2.5-13.1 months). The intermediate-risk group includes patients presenting with a good ECOG PS ≤ 1 but harboring TP53 disruption or not achieving CR after RS induction treatment despite being wild type on TP53 (Events/N, 23/41; median survival, 24.6 months; 95% CI, 15.8-33.4 months). The low-risk group includes patients who presented with a good ECOG PS ≤ 1, had no TP53 disruption, and achieved CR after RS induction treatment (Events/N, 2/11; median survival, not reached; 5-year survival, 70%; 95% CI, 34.4%-100%).

Close Modal

or Create an Account

Close Modal
Close Modal